Ethan Grant joined Gilead Sciences in 2016 and currently leads efforts to implement biomarker analysis strategies in inflammatory bowel disease and autoimmune disease clinical trials. In addition, he leads a cross-functional team within the company exploring the influence of the gut microbiome on therapeutic responses. Prior to Gilead, Ethan provided biomarker expertise for clinical studies in rheumatoid arthritis, lupus and other inflammatory diseases at MedImmune/AstraZeneca and held various positions in early drug development at Schering-Plough and Millennium Pharmaceuticals. Ethan obtained his PhD in Immunology at Harvard University and his BA in Biochemistry, Cell and Molecular Biology at Northwestern University.
The human microbiome has been proposed to form an integral part of human health and its role in disease is a part of large investigations. Furthermore, the microbiome is under evaluation as both a source of therapeutics as well as diagnostics. The current state of the science and medicine in relation to precision medicine approaches will be discussed.